Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | WNT3A | P56704 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17101056 | 0.86 | SCN10A (0.43) | SCN10APTGS1WNT3AMEN1KMT2A | |
| SCHEMBL17101036 | 0.83 | PTGS1 (0.42) | SCN10APTGS1WNT3AMEN1KMT2A | |
| SCHEMBL17101466 | 0.83 | NPC1 (0.56) | SCN10APTGS1WNT3AMEN1KMT2A | |
| SCHEMBL17101044 | 0.82 | POLB (0.45) | MEN1KMT2AHTTSMN1; SMN2POLB | |
| SCHEMBL17101063 | 0.82 | SCN10A (0.47) | SCN10AWNT3AABL1 | |
| SCHEMBL17101104 | 0.81 | WNT3A (0.47) | WNT3A | |
| SCHEMBL16102184 | 0.79 | WNT3A (0.47) | WNT3AKDM4E | |
| SCHEMBL18007163 | 0.78 | TP53 (0.51) | PTGS1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL16098520 | 0.76 | WNT3A (0.61) | SCN10APTGS1WNT3AMEN1KMT2A | |
| SCHEMBL7149522 | 0.75 | MEN1 (0.53) | MEN1KMT2AHTTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114070-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170114070-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-27 | — | — | US | disclosed |
| EP-3119787-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | Bayer Pharma Aktiengesellschaft (DE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140196-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140196-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114070-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | WNT1, WNT3A, CTNNB1 | SCN10A 3776/4885PTGS1 1840/4885WNT3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.